Synapsa® (Bacopa monnieri Extract — KeyView)
Synapsa® is a standardized Bacopa monnieri extract used for memory and cognitive performance. Bacopa is a classic Ayurvedic brain herb, and Synapsa is one of the standardized, bacoside-defined extracts marketed with its own clinical research. The same extract (CDRI 08, sold as KeenMind) was tested in adults in two 12-week trials at 300 mg a day and in two small single-dose studies, which gave mixed results.
Benefits
Memory and learning
Standardized Bacopa monnieri extracts have improved memory and learning measures in randomized trials, with benefits measured after about 12 weeks of daily use. The most brand-relevant evidence is a 12-week trial of the same CDRI 08 extract (sold as Keenmind and Synapsa) that reported gains in learning and memory over the weeks.
Cognitive performance
Trials of standardized Bacopa extracts report modest gains in information processing and recall in healthy adults, which is why Bacopa is described as a slow, cumulative nootropic rather than a same-day one. Results are not uniform across studies; trials of this CDRI 08 extract reported faster information processing and better spatial working memory accuracy.
Lower anxiety scores in small trials
In a 12-week trial of this extract, state anxiety scores fell more than with placebo, and a single-dose study found lower cortisol during a multitasking test. Both were small trials in healthy adults.
Mechanism of action
Bacoside neuroprotection
In laboratory and animal work, bacosides act as antioxidants in brain tissue, support synaptic communication, and promote dendritic growth. These are proposed mechanisms for the memory findings, not effects measured directly in humans.
Neurotransmitter modulation
In lab and animal studies, bacopa influences acetylcholine and serotonin signaling involved in learning and mood.
Clinical trials
Systematic review and network meta-analysis comparing Bacopa monnieri and Ginkgo biloba across cognitive outcomes. This is evidence for standardized Bacopa extracts as a class, not a trial of Synapsa itself. (Tiemtad et al. 2026, Phytomedicine)
Adults across the Bacopa and Ginkgo trials pooled by the review.
This is a pooled analysis of previously published Bacopa and Ginkgo trials rather than a single new study. Doses of 600 mg or more ranked best for working memory and 300 to 600 mg beat placebo for delayed memory; attention and processing speed did not differ. The analysis did not report results for Synapsa specifically.
Side effects and drug interactions
Common Potential side effects
Important Drug interactions
Frequently asked questions about Synapsa® (Bacopa monnieri Extract — KeyView)
What is Synapsa?
Synapsa® is a standardized Bacopa monnieri extract used for memory and cognitive performance. Bacopa is a classic Ayurvedic brain herb, and Synapsa is one of the standardized, bacoside-defined extracts marketed with its own clinical research.
What is Synapsa used for?
Synapsa is researched primarily for Cognitive. Standardized Bacopa monnieri extracts have improved memory and learning measures in randomized trials, with benefits measured after about 12 weeks of daily use.
What is the recommended dosage of Synapsa?
The clinically studied dose is 300 mg a day for 12 weeks in the daily-use trials of this extract (CDRI 08); 320 and 640 mg only in single-dose studies. Always follow the product label and check with a healthcare provider for personal advice.
Is Synapsa safe, and does it have side effects?
Side effects and cautions reported for Synapsa include: Generally well-tolerated — the most common effects are digestive. Mild stomach cramping or loose stools can occur. It may also interact with some medications. Synapsa is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.
Does Synapsa interact with any medications?
Possible interactions include: Thyroid medication — Bacopa may affect thyroid hormone; monitor. Sedatives — possible additive calming effect. If you take prescription medication, check with a pharmacist or doctor before using it.
How strong is the scientific evidence for Synapsa?
NutraSmarts rates the evidence for Synapsa as Limited (2 out of 5). It is backed by 1 study summary and 7 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.
References(7 citations)
Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.
- Comparative effects of Bacopa monnieri and Ginkgo biloba on cognitive functions: A systematic review and network meta-analysis. Phytomedicine. 2026;153:157915..PubMedUsed to support: Systematic review and network meta-analysis of Bacopa monnieri versus Ginkgo biloba cognitive trials; supports Bacopa extracts as a class, not a Synapsa-specific outcome.
- An acute, double-blind, placebo-controlled crossover study of 320 mg and 640 mg doses of a special extract of Bacopa monnieri (CDRI 08) on sustained cognitive performance Phytotherapy Research. 2013;Phytother Res. 2013;27(9):1407-1413.PubMedUsed to support: The most brand-relevant trial available: a double-blind, placebo-controlled crossover study of the CDRI 08 standardized Bacopa extract (the extract marketed as Synapsa) at 320 mg — the dose listed on this page. IMPORTANT: this was an ACUTE single-dose study of sustained cognitive performance, not a multi-week memory trial, so it supports the extract and dose but not the page's cumulative multi-week memory claims.
- The chronic effects of an extract of Bacopa monniera (Brahmi) on cognitive function in healthy human subjects. Psychopharmacology (Berl). 2001;156(4):481-4. doi: 10.1007/s002130100815.PubMedUsed to support: A 12-week double-blind, placebo-controlled trial of the CDRI 08 extract (sold as Keenmind and Synapsa) at 300 mg per day in healthy adults. Speed of visual information processing, learning rate, and memory consolidation improved versus placebo, with maximal effects at 12 weeks. A single small chronic trial.
- Examining the nootropic effects of a special extract of Bacopa monniera on human cognitive functioning: 90 day double-blind placebo-controlled randomized trial. Phytother Res. 2008;22(12):1629-34. doi: 10.1002/ptr.2537.PubMedUsed to support: 90-day randomized, placebo-controlled trial of the CDRI 08 (KeenMind) extract at 2 x 150 mg a day in healthy adults: better spatial working memory accuracy and fewer false alarms on an attention task.
- An acute, double-blind, placebo-controlled cross-over study of 320 mg and 640 mg doses of Bacopa monnieri (CDRI 08) on multitasking stress reactivity and mood. Phytother Res. 2014;28(4):551-9. doi: 10.1002/ptr.5029.PubMedUsed to support: Single-dose crossover study in 17 healthy adults: the CDRI 08 extract improved some multitasking scores 1 and 2 hours after dosing, with some positive mood effects and lower cortisol; the authors call for replication.
- Inhibition of human cytochrome P450 enzymes by Bacopa monnieri standardized extract and constituents. Molecules. 2014;19(2):2588-601. doi: 10.3390/molecules19022588.PubMedUsed to support: Lab study: a standardized bacopa extract inhibited the drug-clearing enzymes CYP2C19, CYP2C9, CYP1A2 and CYP3A4, while isolated bacosides had little effect. Not tested in people.
- Evaluation of memory enhancing clinically available standardized extract of Bacopa monniera on P-glycoprotein and cytochrome P450 3A in Sprague-Dawley rats. PLoS One. 2013;8(8):e72517. doi: 10.1371/journal.pone.0072517.PubMedUsed to support: Rat study: a week of a standardized bacopa extract lowered liver CYP3A activity and raised blood levels of carbamazepine about fourfold. Not tested in people.